|
|
Volumn 25, Issue 3, 2007, Pages 263-
|
|
Incretin mimetics vie for slice of type 2 diabetes market
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DIPEPTIDYL PEPTIDASE IV INHIBITOR;
EXENDIN 4;
GLITAZONE DERIVATIVE;
GLUCAGON LIKE PEPTIDE 1;
INCRETIN;
INSULIN;
METFORMIN;
SAXAGLIPTIN;
SITAGLIPTIN;
SULFONYLUREA;
TROGLITAZONE;
VILDAGLIPTIN;
DISEASE COURSE;
DRUG APPROVAL;
DRUG COST;
DRUG DESIGN;
DRUG DOSE REGIMEN;
DRUG MANUFACTURE;
DRUG SAFETY;
FOOD INTAKE;
HUMAN;
INSULIN RELEASE;
METASTASIS;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NOTE;
PRIORITY JOURNAL;
PROTEIN DEGRADATION;
TUMOR GROWTH;
ADENOSINE DEAMINASE;
ANTIGENS, CD26;
DIABETES MELLITUS, TYPE 2;
DRUG DESIGN;
DRUG INDUSTRY;
GLUCAGON-LIKE PEPTIDE 1;
GLYCOPROTEINS;
HUMANS;
|
|
EID: 33947178492
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0307-263 Document Type: Note |
|
Times cited : (5)
|
|
References (0)
|
